🟢 Telix Pharmaceuticals is trading 8.32% up today after FDA approval of Pixclara for glioma imaging

Telix Pharmaceuticals is trading 8.32% up at $12.76 after the U.S. FDA approved Pixclara on September 14, 2026, for glioma imaging.

• Pixclara is the first FDA-approved FET-PET imaging drug for brain cancer and opens a U.S. commercial opportunity.
• The gain continues the reaction to the company-specific regulatory catalyst.
• Broader U.S. markets are lower ahead of the Federal Reserve meeting, while healthcare-sector strength may provide additional support.